379 results in Exploration of Targeted Anti-tumor Therapy
Most Viewed
Sort by :
- Latest
- Most Viewed
- Most Downloaded
- Most Cited
Open Access
Editorial
Analysis of DNA from liquid biopsy: new genetic biomarkers for cancer immunotherapy?
Carminia Maria Della Corte ... Floriana Morgillo
Published: April 30, 2021 Explor Target Antitumor Ther. 2021;2:204–207
This article belongs to the special issue Liquid Biopsy in Thoracic Cancer
Open Access
Original Article
Effect of vitamin D supplementation on inflammatory markers and total antioxidant capacity in breast cancer women using a machine learning technique
Marzieh Tahmasebi ... Amir Jamshidnezhad
Published: October 30, 2023 Explor Target Antitumor Ther. 2023;4:1059–1070
Open Access
Mini Review
Potential of targeting signal-transducing adaptor protein-2 in cancer therapeutic applications
Taiga Maemoto ... Tadashi Matsuda
Published: March 07, 2024 Explor Target Antitumor Ther. 2024;5:251–259
Open Access
Systematic Review
Management of lung cancer patients during COVID-19 pandemic: dos, don’ts and don’t knows
Mariangela Torniai ... Rossana Berardi
Published: June 10, 2022 Explor Target Antitumor Ther. 2022;3:321–336
This article belongs to the special issue COVID-19 and Cancer
Open Access
Case Report
Is oligoprogression a potentially curable disease in epidermal growth factor receptor mutant lung adenocarcinoma?
Sviatoslav Chekhun ... Maria Saigí
Published: December 13, 2023 Explor Target Antitumor Ther. 2023;4:1182–1187
Open Access
Original Article
Analysis of the benefit of anti-PD-1 monotherapy according to NGS-diagnosed genetic alterations in patients with non-small cell lung cancer
Hortense De Saint Basile ... Elizabeth Fabre
Published: December 18, 2024 Explor Target Antitumor Ther. 2024;5:1435–1449
This article belongs to the special issue Immune Checkpoint Therapy and Biomarkers in Cancer
Open Access
Original Article
Performing oncological procedures during COVID-19 outbreak: a picture from an Italian cancer center
Maristella Bungaro ... Silvia Novello
Published: October 31, 2021 Explor Target Antitumor Ther. 2021;2:481–489
This article belongs to the special issue COVID-19 and Cancer
Open Access
Review
Telehealth in breast cancer following the coronavirus disease 2019 pandemic
Jean Zeghondy ... Barbara Pistilli
Published: December 26, 2023 Explor Target Antitumor Ther. 2023;4:1249–1259
This article belongs to the special issue COVID-19 and Cancer
Open Access
Original Article
Consequences of the impact of COVID-19 pandemic on breast cancer at a single Italian institution
Daniele Ugo Tari ... Fabio Pinto
Published: July 29, 2022 Explor Target Antitumor Ther. 2022;3:414–422
This article belongs to the special issue Covid-19 and Cancer
Open Access
Original Article
Prognostic impact of biomarkers in PMBCL: rationale for early integration of immune checkpoint inhibitors
Yana K. Mangasarova ... Andrey B. Sudarikov
Published: May 20, 2025 Explor Target Antitumor Ther. 2025;6:1002318
This article belongs to the special issue Immune Checkpoint Therapy and Biomarkers in Cancer
Open Access
Meta-Analysis
Comparing efficacy and safety of upfront treatment strategies for anaplastic lymphoma kinase-positive non-small cell lung cancer: a network meta-analysis
Marco Filetti ... Gennaro Daniele
Published: December 01, 2023 Explor Target Antitumor Ther. 2023;4:1136–1144
Open Access
Mini Review
The evolving landscape of first-line and subsequent therapies in EGFR-mutated NSCLC: efficacy, resistance, and tolerability
Carminia Maria Della Corte ... Floriana Morgillo
Published: April 27, 2026 Explor Target Antitumor Ther. 2026;7:1002370
Open Access
Original Article
Exploring the implications of modified advanced lung cancer inflammation index on outcomes in patients with advanced non-small cell lung cancer
Abhishek Mahajan ... Kumar Prabhash
Published: October 11, 2023 Explor Target Antitumor Ther. 2023;4:896–911
This article belongs to the special issue Biomarkers for Personalized and Precise Cancer Diagnosis and Treatment
Open Access
Original Article
Small cell lung cancer: circulating tumor cell lines and expression of mediators of angiogenesis and coagulation
Barbara Rath ... Gerhard Hamilton
Published: April 28, 2023 Explor Target Antitumor Ther. 2023;4:355–365
Open Access
Perspective
Application of explainable artificial intelligence integrating with electronic health record in oncology
Yuhan Yang, Xici Liu
Published: February 04, 2026 Explor Target Antitumor Ther. 2026;7:1002357
Open Access
Original Article
Quantitative peritumoral magnetic resonance imaging fingerprinting improves machine learning-based prediction of overall survival in colorectal cancer
Azadeh Tabari ... Dania Daye
Published: February 19, 2024 Explor Target Antitumor Ther. 2024;5:74–84
This article belongs to the special issue Artificial Intelligence for Precision Oncology
Open Access
Original Article
Evaluation of antitumor potential of an anti-glypican-1 monoclonal antibody in preclinical lung cancer models reveals a distinct mechanism of action
Minghua Li ... Qingyu Zhou
Published: June 17, 2024 Explor Target Antitumor Ther. 2024;5:600–626
This article belongs to the special issue Molecular Diagnosis and Personalized Therapy of Cancer
Open Access
Case Report
Cystic presentation of primary hepatic neuroendocrine tumour: a case report with a brief review of literature
Mangesh Londhe ... Charusheela Gore
Published: April 26, 2023 Explor Target Antitumor Ther. 2023;4:266–272
This article belongs to the special issue Precision Medicine for Cholangiocarcinoma
Open Access
Original Article
Concomitant exposure to benzodiazepines during pembrolizumab-based therapy for advanced non-small-cell lung cancer: a propensity-score matched analysis of monitoring agency data
Fabrizio Nelli ... Agnese Fabbri
Published: January 20, 2025 Explor Target Antitumor Ther. 2025;6:1002287
This article belongs to the special issue Immune Checkpoint Therapy and Biomarkers in Cancer
Open Access
Perspective
Cancer symptom cluster research in pediatric oncology: a work in progress
Luciana Chain Veronez, Luís Carlos Lopes-Júnior
Published: April 24, 2024 Explor Target Antitumor Ther. 2024;5:400–408
Previous